Valuation: Lineage Cell Therapeutics, Inc.

Market Cap 329M 288M 265M 246M 467M 31.23B 474M 3.18B 1.24B 15.41B 1.24B 1.21B 53.28B P/E 2026 *
-18.9x
P/E 2027 * -14.4x
Enterprise Value 329M 288M 265M 246M 467M 31.23B 474M 3.18B 1.24B 15.41B 1.24B 1.21B 53.28B EV / Sales 2026 *
18.3x
EV / Sales 2027 * 18.2x
Free-Float
95.07%
Yield 2026 *
-
Yield 2027 * -
1 day-0.75%
1 week+0.76%
Current month+0.76%
1 month+10.92%
3 months-13.16%
6 months-27.87%
Current year-20.96%
1 week 1.29
Extreme 1.29
1.38
1 month 1.18
Extreme 1.18
1.38
Current year 1.18
Extreme 1.18
1.98
1 year 0.93
Extreme 0.9296
2.09
3 years 0.37
Extreme 0.3651
2.09
5 years 0.37
Extreme 0.3651
2.8
10 years 0.37
Extreme 0.3651
4
Manager TitleAgeSince
Chief Executive Officer 54 16/09/2018
Director of Finance/CFO 50 13/11/2022
Chief Operating Officer - 30/11/2010
Director TitleAgeSince
Director/Board Member 60 30/06/2009
Director/Board Member 68 10/04/2014
Chairman 60 26/04/2024
Date Insider Type Main position Quantity % Market Cap.
06-30Free

Director

125,000 0.0501%
06-30Free

Director

125,000 0.0501%
06-30Free

Director

125,000 0.0501%
Change 5-day change 1-year change 3-year change Capi.($)
-0.75%+0.76%+38.89%-3.65% 329M
-1.08%+3.92%+1.65%+8.04% 49.74B
+0.25%+1.70%+419.39%+621.71% 40.49B
-0.16%+8.42%+28.20%+63.00% 34.35B
+1.10%+7.77%+28.18%-3.96% 34.75B
+1.31%-0.56%+5.12%+33.90% 26.98B
-0.35%+0.09% - - 16.58B
-3.33%+3.15%+71.30%+131.94% 15.6B
+3.79%+8.88%+106.63%+106.63% 14.27B
-2.87%-2.22%+12.16%+17.56% 13.76B
Average -0.20%+3.87%+79.06%+108.35% 24.69B
Weighted average by Cap. -0.07%+4.58%+95.38%+140.42%

Financials

2026 *2027 *
Net sales 17.94M 15.7M 14.47M 13.41M 25.45M 1.7B 25.86M 173M 67.46M 840M 67.34M 65.88M 2.9B 18.09M 15.83M 14.59M 13.52M 25.67M 1.72B 26.09M 175M 68.04M 847M 67.93M 66.46M 2.93B
Net income -23.79M -20.82M -19.18M -17.78M -33.76M -2.26B -34.3M -230M -89.46M -1.11B -89.31M -87.37M -3.85B -31.66M -27.71M -25.53M -23.67M -44.93M -3B -45.65M -306M -119M -1.48B -119M -116M -5.13B
Net Debt - -
Logo Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing cell replacement therapies to treat serious medical conditions. The Company programs are based on a cell-based technology platform, AlloSCOPE, which develops formulation, manufacturing, and delivery capabilities, and serves as the source of its pluripotent cell-based product candidates. Its pipeline includes OpRegen, an allogeneic retinal pigment epithelial (RPE) cell replacement therapy for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (dry-AMD); OPC1, an allogeneic oligodendrocyte progenitor cell therapy for the treatment of spinal cord injuries (SCI); ReSonance (ANP1), an allogeneic auditory neuron progenitor cell transplant therapy for the treatment of auditory neuropathy; ILT1, an allogeneic cell transplant research initiative for the treatment of Type 1 Diabetes (T1D).
Employees
75
Date Price Change Volume
07/07/26 US$1.320 -0.75% 680,001
06/07/26 US$1.330 -1.48% 842,935
02/07/26 US$1.350 +3.85% 724,037
01/07/26 US$1.300 -0.76% 775,272
30/06/26 US$1.310 -2.96% 865,791
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
1.320USD
Average target price
5.500USD
Spread / Average Target
+316.67%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. LCTX Stock